Subchronic toxicity and toxicokinetics of MCC-555, a novel thiazolidinedione, after 270-day repeated oral administration in dogs

Environmental Toxicology and Pharmacology

Volumn 27, Issue 2, 2009, Pages 237-246

  Sun, Ning ^a,b,c   Lu, Guocai ^a   Lin, Mei ^d   Fan, Guorong ^a,b,c   Wu, Yutian ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI KEY LABORATORY FOR PHARMACEUTICAL METABOLITE RESEARCH   (China)

^c Shanghai Research Centre for Drug Chinese Materia Medica Metabolism   (China)

^d SHANGHAI INSTITUTE FOR FOOD AND DRUG CONTROL   (China)

Author keywords

Beagle dogs; MCC 555; Subchronic toxicity; Toxicokinetics

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; NETOGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MARROW; CELL INFILTRATION; CHRONIC TOXICITY; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG PENETRATION; ELECTROCARDIOGRAPHY MONITORING; FATTY LIVER; FEMALE; FOOD INTAKE; HISTOPATHOLOGY; INFLAMMATORY CELL; KIDNEY; LIVER; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SUBCHRONIC TOXICITY; TESTIS; TOXICOKINETICS; URINALYSIS; VOMITING;

CANIS FAMILIARIS;

EID: 59649111191     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etap.2008.10.011     Document Type: Article

References (32)

1. Ali A.A., Weinstein R.S., Stewart S.A., Parfitt A.M., Manolagas S.C., and Jilka R.L. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology (2004) 1226-1235
2. Arakawa K., Ishihara T., Aoto M., Inamasu M., Saito A., and Ikezawa K. Action of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells. British journal of pharmacology 125 (1998) 429-436
3. Barman Balfour J.A., and Plosker G.L. Rosiglitazone. Drugs 57 (1999) 921-930
4. Basu A., Jensen M.D., McCann F., Mukhopadhyay D., Joyner M.J., and Rizza R.A. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 29 (2006) 510-514
5. Bedir A., Aliyazicioglu Y., Bilgici B., Yurdakul Z., Uysal M., Suvaci D.E., Okuyucu A., Kahraman H., Hökelek M., and Alvur M. Assessment of genotoxicity in rats treated with the antidiabetic agent, pioglitazone. Environmental and molecular mutagenesis 49 (2008) 185-191
6. Berger J., Bailey P., Biswas C., Cullinan C.A., Doebber T.W., Hayes N.S., Saperstein R., Smith R.G., and Leibowitz M.D. Thiazolidinediones produce a conformational change in peroxisomal proliferator activated receptor-g: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137 (1996) 4189-4195
7. Buckingham R.E., Al-Barazanji K.A., Toseland C.D.N., Slaughter M., Connor S.C., West A., Bond B., Turner N.C., and Clapham J.C. Peroxisome proliferator-activated receptor-g agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47 (1998) 1326-1334
8. DeFronzo R.A. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15 (1992) 318-368
9. Fujiwara T., Yoshioka S., Yoshida T., Ushiyama I., and Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37 (1988) 1549-1558
10. Gillies P.S., and Dunn C.J. Pioglitazone. Drugs 60 (2000) 333-343
11. Khan M.A., St Peter J.V., and Xue J.L. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25 (2002) 708-711
12. Kim J.C., Kang B.H., Shin C.C., Kim Y.B., Lee H.S., Kim C.Y., Han J., Kim K.S., Chung D.W., and Chung M.K. Subchronic toxicity of plant sterol esters administered by gavage to Sprague-Dawley rats. Food and Chemical Toxicology 40 (2002) 1369-1380
13. King A.B. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 23 (2000) 557
14. Lecka-Czernik B., Moerman E.J., Grant D.F., Lehmann J.M., Manolagas S.C., and Jilka R.L. Divergent effects of selective peroxisome proliferator activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143 (2002) 2376-2384
15. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). The Journal of biological chemistry 270 (1995) 12953-12956
16. Loi C.M., Young M., Randinitis E., Vassos A., and Koup J.R. Clinical pharamockinetics of troglitazone. Clinical pharmacokinetics 37 (1999) 91-104
17. Murakami K., Tobe K., Ide T., Mochizuki T., Ohashi M., Akanuma Y., Yazaki Y., and Kadowaki T. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ. Diabetes 47 (1998) 1841-1847
18. Ning S., Mei L., Guorong F., Zhanying H., and Guocai L. Quantitative determination of MCC-555, a novel insulin sensitizer in beagle dog plasma by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B 835 (2006) 35-39
19. Oxana P.L., Sylwia O.R., Larry J.S., and Beata L.C. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 38 (2006) 74-84
20. Plosker G.L., and Faulds D. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 57 (1999) 409-438
21. Pickavance L., Widdowson P.S., King P., Ishii S., Tanaka H., and Williams G. The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment. British journal of pharmacology 125 (1998) 767-770
22. Rawiwan M., Ayaka S., Shuichi K., Ikuo Y., Takanobu W., Takeshi S., Kanefusa K., Shogo T., Miki N., and Tsuyoshi Y. Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. Toxicology 216 (2005) 15-23
23. Reaven G.M. Physiology of insulin resistance in human disease. Physiological reviews 75 (1995) 473-486
24. Reginato M.J., Bailey S.T., Krakow S.L., Minami C., Ishii S., Tanaka H., and Lazar M.A. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma activating properties. The Journal of biological chemistry 273 (1998) 32679-32684
25. Rzonca S.O., Suva L.J., Gaddy D., Montague D.C., and Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145 (2004) 401-406
26. Scott L., Michael J.H., Yumiko S., Andrew F., Paul M.S., Nicola J.H., and Albert P.L. Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Chemico-Biological Interactions 142 (2002) 57-71
27. Soroceanu M.A., Miao D., Bai X.Y., Su H., Goltzman D., and Karaplis A.C. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. The Journal of endocrinology 183 (2004) 203-216
28. Spiegelman B.M. PPAR-g: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 (1998) 507-514
29. Upton R., Widdowson P.S., Ishii S., Tanaka H., and Williams G. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. British journal of pharmacology 125 (1998) 1708-1714
30. Werner A.L., and Travaglini M.T. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21 (2002) 1082-1099
31. Willson T.M., Cobb J.E., Cowan D.J., Wiehte R.W., Correa I.D., Prakash S.R., Beck K.D., Moore L.B., Kliewer S.A., and Lehmann J.M. The structure-activity relationship between peroxisome proliferator-activated receptor-g agonism and the antihyperglycemic activity of the thiazolidinediones. Journal of medicinal chemistry 39 (1996) 665-668
32. Young P.W., Cawthorne M.A., Coyle P.J., Holder J.C., Holman G.D., Kozka I.J., Kirkham D.M., Lister C.A., and Smith S.A. Repeated treatment of obese mice with BRL49653, a new and potent insulin sensitizer, enhances insulin action in white adipocyte: association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 44 (1995) 1087-1092